Loading clinical trials...
Loading clinical trials...
A Phase 1/2a, First-in-human, Oral Single and Multiple Dose-escalation, Randomized, Double-blinded, Placebo-controlled Study of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria to Evaluate Safety, Tolerability, Kinetics, and Pharmacodynamics
Conditions
Interventions
SYNB1618
Placebo
Locations
4
United States
Boston Children's Hospital
Boston, Massachusetts, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
PRA Health Sciences
Salt Lake City, Utah, United States
Start Date
April 17, 2018
Primary Completion Date
June 21, 2019
Completion Date
June 21, 2019
Last Updated
May 13, 2021
NCT06716502
NCT07310264
NCT00090662
NCT06290258
NCT07483606
NCT06342713
Lead Sponsor
Synlogic
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions